Back to results
US 10,117,869 B2Granted
PDE III inhibitors for treatment of asymptomatic heart failure
AssigneeBoehringer Ingelheim Vetmedica GmbH
InventorsJuergen Daemmgen, Olaf Joens, Rainer Kleemann, Christian Troetschel, Andrea Vollmar
Life of this patent
Estimating the term…
Abstract
Phosphodiesterase type III (PDE III) inhibitor or a “Ca2+-sensitizing agent” or a pharmaceutically acceptable derivative thereof is used in the preparation of a medication for the reduction of the heart size of a patient suffering from heart failure, and as a medication for the reverse remodeling of the heart of a patient with asymptomatic (occult) heart failure and their delayed onset of clinical symptoms.
Claims15
An article of manufacture including:
- packaging material;
- and
- at least one pharmaceutical composition contained in the packaging material, the at least one pharmaceutical composition comprising:
- a therapeutically effective amount of a phosphodiesterase type III (PDE III) inhibitor comprising pimobendan, wherein said therapeutically effective amount is effective to prolong time until onset of clinical symptoms of heart disease and/or to reduce heart size for a patient having ISACHC (International Small Animal Cardiac Health Council) Class I heart failure;
- and
- a second active therapeutic agent consisting of at least three of benazepril, enalapril, spironolactone, and furosemide.
3 more elements
A pharmaceutical composition comprising:
- a therapeutically effective amount of a phosphodiesterase type III (PDE III) inhibitor comprising pimobendan, wherein said therapeutically effective amount is effective to prolong time until onset of clinical symptoms of heart disease and/or to reduce heart size for a patient having ISACHC (International Small Animal Cardiac Health Council) Class I heart failure;
- and
- a second active therapeutic agent consisting of at least three of benazepril, enalapril, spironolactone, and furosemide;
- wherein the pharmaceutical composition includes the PDE III inhibitor and the second active therapeutic agent within a single dosage unit.
1 more element
Dependencies are inferred from the claim text.